|
1）Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008; 52: 818-27
|
|
|
|
2）Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006; 27: 1440-6
|
|
|
|
|
|
3）Olivetti G, Quaini F, Lagrasta C, et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol. 1992; 141: 227-39
|
|
|
|
|
|
4）Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004; 110: 149-54
|
|
|
|
|
|
5）Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005; 1121-7
|
|
|
|
|
|
6）Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007; 9: 872-8
|
|
|
|
|
|
7）Belonje AM, Voors AA, van der Meer P, et al. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010; 121: 245-51
|
|
|
|
|
|
8）Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997; 100: 2310-4
|
|
|
|
|
|
9）van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circula-tion. 2005; 112: 1743-7
|
|
|
|
|
|
10）La Ferla K, Reimann C, Jelkmann W, et al. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J. 2002; 16: 1811-3
|
|
|
|
|
|
11）Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352; 1011-23
|
|
|
|
|
|
12）Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005; 26: 2232-7
|
|
|
|
|
|
13）Androne AS, Katz SD, Lund L, et al. Hemo-dilution is common in patients with advanced heart failure. Circulation. 2003; 21; 107: 226-9
|
|
|
|
|
|
14）Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008; 52: 501-11
|
|
|
|
|
|
15）de Silva R, Rigby AS, Witte KK, et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol. 2006; 98; 391-8
|
|
|
|
|
|
16）Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006; 48: 2485-9
|
|
|
|
|
|
17）Gonzalez-Costello J, Comin-Colet J. Iron deficiency and anaemia in heart failure: under-standing the FAIR-HF trial. Eur J Heart Fail. 2010; 12: 1159-62
|
|
|
|
|
|
18）Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000; 35: 1737-44
|
|
|
|
|
|
19）Kotecha D, Ngo K, Walters JA, et al. Eryth-ropoietin as a treatment of anemia in heart fail-ure: systematic review of randomized trials. Am Heart J. 2011; 161: 822-31
|
|
|
|
|
|
20）McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009; 11: 795-801
|
|
|
|
|
|
21）Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-98
|
|
|
|
|
|
22）Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361: 2436-48
|
|
|
|
|